Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,034.00
Bid: 12,032.00
Ask: 12,034.00
Change: 104.00 (0.87%)
Spread: 2.00 (0.017%)
Open: 12,108.00
High: 12,142.00
Low: 11,994.00
Prev. Close: 11,930.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data

Tue, 13th Feb 2024 16:53

(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.

The FTSE 100 index closed down 61.41 points, 0.8%, at 7,512.28. The FTSE 250 ended down 280.10 points, 1.5%, at 18,923.83, and the AIM All-Share closed down 2.85 points, 0.4%, at 747.33.

The Cboe UK 100 ended down 0.9% at 750.56, the Cboe UK 250 closed down 1.7% at 16,341.91, and the Cboe Small Companies ended down 0.2% at 14,364.40.

In European equities on Tuesday, the CAC 40 in Paris and the DAX 40 in Frankfurt both closed down 0.9%.

Stocks in New York were lower at the London equities close, with the DJIA down 1.1%, the S&P 500 index down 1.0%, and the Nasdaq Composite down 1.2%.

The US inflation rate cooled but at a slower pace than expected last month, key figures on Tuesday showed.

According to the Bureau of Labor Statistics, the nation's consumer price inflation rate eased to 3.1% in January, from 3.4% in December. It had been expected to ebb to 2.9%, according to FXStreet cited consensus, so the latest reading topped expectations.

Annual core inflation, so excluding food and energy, was steady at 3.9% in January, defying expectations of a slowdown to 3.7%.

"US inflation failed to moderate as hoped with housing costs, air fares, medical care and recreation all keeping the run rate for month-on-month inflation hot. Their favoured measure of inflation, the core PCE deflator, may be cooling nicely, but the mixed messages means the Fed can't relax, with little inclination for imminent rate cuts," said ING's James Knightley.

The reading all but ensures that any tiny thread of hope that the Federal Reserve will cut interest rates next month were extinguished. Investors are looking to May for the first Fed cut of the year, though Tuesday's data could dampen that hope.

Ebury's Matthew Ryan said that a May cut is now "in serious jeopardy."

Ryan added: "We stand by our call for a start to the Fed's cutting cycle in June, albeit this would also be thrown in doubt should US inflation continue to surprise to the upside, while the labour market shows no signs of slowing down."

The dollar was mostly stronger on the back of the reading.

The pound was quoted at USD1.2596 at the London equities close Tuesday, down compared to USD1.2621 at the close on Monday. The euro stood at USD1.0716 at the European equities close Tuesday, down against USD1.0769 at the same time on Monday.

Against the yen, the dollar was trading at JPY150.66, higher compared to JPY149.44 late Monday.

Meanwhile, in the UK, there was also some key economic data for investors to digest.

According to the Office for National Statistics, the jobless rate faded to 3.8% in the three months to the end of December from 4.2% in the period from September to November.

Unemployment had been expected to ease slightly less, to 4.0%, according to FXStreet-cited market consensus.

Annual growth in regular earnings, so excluding bonuses, amounted to 6.2% in the three months to December. Including bonuses, earnings rose 5.8% on-year.

Pay growth was hotter than expected by both measures. Earnings including bonuses had been expected to rise by 5.6%, according to FXStreet, while excluding bonuses, a rise of 6.0% was forecast.

"Stronger than expected labour data from the UK didn't help matters as it effectively gives the Bank of England another reason to keep rates steady and not rush to cut them," AJ Bell's Russ Mould explained.

The BoE's next decision is on March 21.

On Wednesday, the ONS reports UK inflation data for January. Annual consumer price inflation is expected to have picked up to 4.2% last month from 4.0% in December, according to FXStreet.

In London, property firms were among the worst large-cap performers following the red-hot UK data.

Property portal Rightmove fell 3.0%, while housebuilders Taylor Wimpey, Persimmon, and Barratt Developments fell 4.4%, 4.1% and 4.6%.

There were just eight FTSE 100 companies in the green. Amogst them, pharmaceutical firms AstraZeneca and GSK were up 1.0% and 1.1%, respectively.

In the FTSE 250, Tui shares closed up 0.8%.

Tui's pretax loss narrowed to EUR103.1 million in the three months that ended December 31 from EUR272.6 million a year before, as revenue rose by 15% to a "record" EUR4.30 billion from EUR3.75 billion.

On London's AIM, Saietta plummeted 54%.

The Towcester, England-based manufacturer said it would be selling a redundant production line after missing out on a potentially lucrative manufacturing contract.

The company has received a proposal of GBP600,000 from an unnamed buyer for the purchase of a redundant production line at its Sunderland manufacturing site.

Saietta said that the sale is the result of the company being unable to reach a commercial agreement for a contract to product electrical steering pumps at the Sunderland plant.

Brent oil was quoted at USD82.93 a barrel at the London equities close Tuesday, up from USD81.69 late Monday.

Gold was quoted at USD1,995.88 an ounce at the London equities close Tuesday, lower against USD2,013.55 at the close on Monday.

In Wednesday's UK corporate calendar, there are full year results from Coca-Cola HBC. There are also trading statements from Severn Trent and United Utilities.

The economic calendar for Wednesday has a gross domestic product reading for the eurozone at 1000 GMT, as well as employment data.

For the UK, there are CPI and PPI readings at 0700 GMT. Further at 1500 GMT, Bank of England Governor Andrew Bailey will speak.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved..

More News
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.